CD3+CD56+natural killer T cells in fibromyalgia syndrome patients: Association with the intensity of depression

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.79, 2013, Pages 9-15

  Nugraha, Boya ^a,b   Korallus, Christoph ^a   Kielstein, Heike ^a,c   Gutenbrunner, Christoph ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF INDONESIA   (Indonesia)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Depression; Fibromyalgia; Mental symptom; NKT cells

Indexed keywords

ANTIDEPRESSANT AGENT; CD3 ANTIGEN; CD56 ANTIGEN;

ADULT; AGE; AGED; ANXIETY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFECT; DRUG USE; FATIGUE; FEMALE; FIBROMYALGIA; FLUORESCENCE ACTIVATED CELL SORTING; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LYMPHOCYTE COUNT; MALE; NATURAL KILLER T CELL; PAIN ASSESSMENT; PRIORITY JOURNAL;

EID: 84892467174     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. WOLFE F, SMYTHE HA, YUNUS MB et al.: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160- 72.
2. LAWRENCE RC, FELSON DT, HELMICK CG et al.: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58: 26- 35.
3. EICH W, HäUSER W, FRIEDEL E et al.: [Definition, classification and diagnosis of fibromyalgia syndrome]. Schmerz 2008; 22: 255-66.
4. FIETTA P, FIETTA P, MANGANELLI P: Fibromyalgia and psychiatric disorders. Acta Biomed 2007; 78: 88-95.
5. ULUS Y, AKYOL Y, TANDER B et al.: Sleep quality in fibromyalgia and rheumatoid arthritis: associations with pain, fatigue, depression, and disease activity. Clin Exp Rheumatol 2011; 29: S92-96.
6. ALOK R, DAS SK, AGARWAL GG, SALWAHAN L, SRIVASTAVA R: Relationship of severity of depression, anxiety and stress with severity of fibromyalgia. Clin Exp Rheumatol 2011; 29: S70-72.
7. BAZZICHI L, SERNISSI F, CONSENSI A, GIACOMELLI C, SARZI-PUTTINI P: Fibromyalgia: a critical digest of the recent literature. Clin Exp Rheumatol 2011; 29: S1-11.
8. WOLFE F, CLAUW DJ, FITZCHARLES MA et al.: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arth Care Res 2010; 62: 600-10.
9. CARVILLE SF, ARENDT-NIELSEN S, BLIDDAL H et al: EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008; 67: 536-41.
10. HAUSER W, THIEME K, TURK DC: Guidelines on the management of fibromyalgia syndrome -a systematic review. Eur J Pain 2010; 14: 5-10.
11. NUGRAHA B, NEUES-LAHUSEN M, CANDIR F, GUTENBRUNNER C: Effect of a series of H2S mineral water bathing on pain in patients with fibromalgia syndrome -A pilots study. Phys Med Rehab Kuror 2011; 21: 284-9.
12. SANUDO B, GALIANO D, CARRASCO L, de HOYO M, McVEIGH JG: Effects of a prolonged exercise programme on key health outcomes in women with fibromyalgia: A randomized controlled trial. J Rehab Med 2011; 43: 521-6.
13. BIRCAN C, KARASEL SA, AKGüN B, EL ö, ALPER S: Effects of muscle strengthening versus aerobic exercise program in fibromyalgia. Rheumatol Int 2008; 28: 527-32.
14. BENNETT R, NELSON D: Cognitive behavioral therapy for fibromyalgia. Rheumatology 2006; 2: 416-24.
15. Van KOULIL S, van LANKELD.W, KRAAIMAAT FW et al.: Tailored cognitive-behavioral therapy and exercise training for high-risk patients with fibromyalgia. Arthritis Care and Res 2010; 62: 1377-85.
16. VAZQUEZ-RIVERA S, GONZáLEZ-BLANCH C, RODRíGUEZ-MOYA L, MORóN D, GONZáLEZ-VIVES S, CARRASCO JL: Brief cognitive-behavioral therapy with fibromyalgia patients in routine care. Compr Psychiatry 2009; 50, 517-25
17. WILSON B, SPENCER H, KORTEBEIN P: Exercise recommendations in patients with newly diagnosed fibromyalgia. PMR 2012; 4: 252-5.
18. GODFREY RG: A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Arch Intern Med 1996; 156: 1047-52.
19. GUR A, OKTAYOGLU P: Status of immune mediators in fibromyalgia. Curr Pain Headache Rep 2008; 12: 175-81.
20. MENZIES V, LYON DE: Integrated review of the association of cytokines with fibromyalgia and fibromyalgia core symptoms. Biol Res Nurs 2010; 11: 387-94.
21. VIVIER E, RAULET DH, MORETTA A et al.: Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331: 44-9.
22. RUSSELL IJ, VIPRAIO GA, MICHALEK JE, CRAIG FE, KANG YK, RICHARDS AB: Lymphocyte markers and natural killer cell activity in fibromyalgia syndrome: effects of low-dose, sublingual use of human interferon-alpha. J Interferon Cytokine Res 1999; 19: 969-78.
23. LANDIS SE: Illustrating local community initiative in mental health reform: the management and treatment of depression by primary care physicians. N C Med J 2003; 64: 228-30.
24. LAMKIN DM, LUTGENDORF SK, McGINN S et al: Positive psychosocial factors and NKT cells in ovarian cancer patients. Brain Behav Immun 2008; 22: 65-73.
25. LANIER LL, LE AM, CIVIN CI, LOKEN MR, PHILLIPS JH: The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986; 136: 4480-6.
26. SCHMIDT RE, MURRAY C, DALEY JF, SCHLOSSMAN SF, RITZ J: A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med 1986; 164: 351-6.
27. KRONENBERG M: Toward an understanding of NKT cell biology: progress and paradoxes. AnnuRev Immunol 2005; 23: 877-900.
28. BENDELAC A, SAVAGE PB, TEYTON L: The biology of NKT cells. Annu Rev Immunol 2007; 25: 297-336.
29. BERZINS SP, SMYTH MJ, BAXTER AG: Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011; 11: 131-42.
30. van der VLIET HJ, NISHI N, KOEZUKA Y et al.: Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J Immunol Methods 2001; 247: 61-72.
31. ILLéS Z, KONDO T, NEWCOMBE J, OKA N, TABIRA T, YAMAMURA T: Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 2000; 164: 4375-81.
32. GRITZAPIS AD, DIMITROULOPOULOS D, PARASKEVAS E, BAXEVANIS CN, PAPA-MICHAIL M: Large-scale expansion of CD3(+) CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunol Immunother 2002; 51: 440-8.
33. BOUHUYS AL, FLENTGE F, OLDEHINKEL AJ, van den BERG MD: Potential psychosocial mechanisms linking depression to immune function in elderly subjects. Psychiatry Res 2004; 127: 237-45.
34. DUPONT WD, PWJ PS: Power and sample size calculation. 2009. Version 3.0 http://biostat. mc.vanderbilt.edu/wiki/Main/PowerSample-Size.
35. ZIGMOND AS, SNAITH RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
36. FIRST MB, SR, GIBBON M, WILLIAMS JBW: Structured Clinical interview for DSM-IV Axis I disorders. Biometrics Research Department, New York State Psychiatric Institute. 1995; Patient Edition (SCID-I/P, Version 2.0).
37. ARNOLD LM, PALMER RH, GENDREAU RM, CHEN W: Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran. Psychosomatics 2012; 53: 371-9.
38. COSCO TD, DOYLE F, WARD M, McGEE H: Latent structure of the Hospital Anxiety And Depression Scale: a 10-year systematic review. J Psychosom Res 2012; 72: 180-4.
39. SAMBORSKI W, LACKI JK, WIKTOROWICZ KE: The lymphocyte phenotype in patients with primary fibromyalgia. Ups J Med Sci 1996; 101: 251-6.
40. LUTGENDORF SK, MOORE MB, BRADLEY S, SHELTON BJ, LUTZ CT: Distress and expression of natural killer receptors on lymphocytes. Brain Behav Immun 2005; 19: 185-94.
41. PARK EJ, LEE JH, CHAE JH, LEE KH, HAN SI, JEON YW: Natural Killer T cells in patients with major depressive disorder. Psychiatry Res 2006; 144: 237-9.
42. BRADLEY LA: Pathophysiology of fibromyalgia. Am J Med 2009; 122: S22-30.
43. KALLEN VL, TULEN JH, UTENS EM, TREFFERS PD, De JONG FH, FERDINAND RF: Associations between HPA axis functioning and level of anxiety in children and adolescents with an anxiety disorder. Depress Anxiety 2008; 25: 131-41.
44. BESEDOVSKY HO, Del REY A: The cytokine-HPA axis feed-back circuit. Z Rheumatol 2000; 59 (Suppl. 2): II/26-30.
45. VIVEROS-PAREDES JM, PUEBLA-PEREZ AM, GUTIERREZ-CORONADO O, SANDOVALRAMIREZ, L, VILLASENOR-GARCIA MM: Dysregulation of the Th1/Th2 cytokine profile is associated with immunosuppression induced by hypothalamic-pituitary-adrenal axis activation in mice. Int Immunopharmacol 2006; 6: 774-81.
46. TANIGUCHI M, NAKAYAMA T: Recognition and function of Valpha14 NKT cells. Semin Immunol 2000; 12: 543-50.
47. SHI FD, LJUNGGREN HG, SARVETNICK N: Innate immunity and autoimmunity: from self-protection to self-destruction. Trends Immunol 2001; 22: 97-101.
48. KADETOFF D, KOSEK E: Evidence of reduced sympatho-adrenal and hypothalamicpituitary activity during static muscular work in patients with fibromyalgia. J Rehabil Med 2010; 42: 765-72.
49. DIMITROV S, LANGE T, BORN J: Selective mobilization of cytotoxic leukocytes by epinephrine. J Immunol 2010; 184: 503-11.
50. SCHEDLOWSKI M, HOSCH W, OBERBECK R et al.: Catecholamines modulate human NK cell circulation and function via spleenindependent beta 2-adrenergic mechanisms. J Immunol 1996; 156: 93-9.
51. VARGAS-ALARCóN G, FRAGOSO JM, CRUZROBLES D et al.: Association of adrenergic receptor gene polymorphisms with different fibromyalgia syndrome domains. Arthritis Rheum 2009; 60: 2169-73.
52. CARLSON SL, BEITING DJ, KIANI CA, ABELL KM, McGILLIS JP: Catecholamines decrease lymphocyte adhesion to cytokine-activated endothelial cells. Brain Behav Immun 1996; 10: 55-67.
53. KOHM AP, SANDERS VM: Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. Pharmacol Rev 2001; 53: 487-525.